Sofosbuvir + velpatasvir + voxilaprevir for the treatment of hepatitis C infection

References

• Polaris Observatory HCVC. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017 Mar;2(3):161–176.
   PubMed Web of Science ®Google Scholar
• McGivern DR, Masaki T, Lovell W, et al. Protease inhibitors block multiple functions of the ns3/4a protease-helicase during the hepatitis C virus life cycle. J Virol. 2015 May;89(10):5362–5370.
   PubMed Web of Science ®Google Scholar
• Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013 May 16;368(20):1867–1877.
   PubMed Web of Science ®Google Scholar
• Pawlotsky JM. NS5A inhibitors in the treatment of hepatitis C. J Hepatol. 2013 Aug;59(2):375–382.
   PubMed Web of Science ®Google Scholar
• Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011 Jun 23;364(25):2405–2416.
   PubMed Web of Science ®Google Scholar
• Pawlotsky JM. Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens. Gastroenterology. 2016 Jul;151(1):70–86.
   PubMed Web of Science ®Google Scholar
• VOSEVI® (sofosbuvir, velpatasvir, and voxilaprevir) package insert. Foster City (CA): Gilead Sciences, Inc; 2017.
   Google Scholar
• Murakami E, Tolstykh T, Bao H, et al. Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977. J Bio Chem. 2010;285(45):34337–34347.
   PubMed Web of Science ®Google Scholar
• Fung A, Jin Z, Dyatkina N, et al. Efficiency of incorporation and chain termination determines the inhibition potency of 2′-modified nucleotide analogs against hepatitis C virus polymerase. Antimicrob Agents Chemother. 2014;58(7):3636–3645.
   PubMed Web of Science ®Google Scholar
• Besandre R, Liu H-W. Biochemical basis of Vosevi, a new treatment for hepatitis C. Biochemistry. 2018;57:479–480.
   Google Scholar
• Lim PJ, Chatterji U, Cordek D, et al. Correlation between NS5A dimerization and hepatitis C virus replication. J Biol Chem. 2012;287(36):30861–30873.
   PubMed Web of Science ®Google Scholar
• Belema M, Lopez OD, Bender JA, et al. Discovery and development of hepatitis C virus NS5A replication complex inhibitors. J Med Chem. 2014;57(5):1643–1672.
   PubMed Web of Science ®Google Scholar
• Götte M, Feld JJ Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights. Nat Rev Gastroenterol Hepatol. 2016;13(6):338–351.
   PubMed Web of Science ®Google Scholar
• Sofia MJ, Bao D, Chang W, et al. Discovery of a β-d-2′-Deoxy-2′-α-fluoro-2′-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. J Med Chem. 2010 2010 Oct 14;53(19):7202–7218.
   PubMed Web of Science ®Google Scholar
• Lam AM, Espiritu C, Bansal S, et al. Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. Antimicrob Agents Chemother. 2012;56(6):3359–3368.
   Google Scholar
• Lawitz EJ, Dvory-Sobol H, Doehle BP, et al. Clinical resistance to velpatasvir (GS-5816), a novel pan-genotypic inhibitor of the hepatitis C virus NS5A protein. Antimicrob Agents Chemother. 2016;60(9):5368–5378.
   PubMed Web of Science ®Google Scholar
• Klein S, Rick J, Schierwagen R, et al. Jak2/Arhgef1 signaling correlates with severity of liver disease and represents a target for therapy of portal hypertension. Hepatology. 2014;60:302a.
   Web of Science ®Google Scholar
• Taylor J, Appleby T, Barauskas O, et al. P0899: preclinical profile of the pan-genotypic HCV NS3/4A protease inhibitor GS-9857. J Hepatol. 2015;62:S681.
   Web of Science ®Google Scholar
• Mogalian E, German P, Kearney BP, et al. Preclinical pharmacokinetics and first-in-human pharmacokinetics, safety, and tolerability of velpatasvir, a pangenotypic hepatitis C virus NS5A inhibitor, in healthy subjects. Antimicrob Agents Chemother. 2017;61(5):e02084–16.
   PubMed Web of Science ®Google Scholar
• Rodriguez‐Torres M, Glass S, Hill J, et al. GS‐9857 in patients with chronic hepatitis C virus genotype 1–4 infection: a randomized, double‐blind, dose‐ranging phase 1 study. J Viral Hepat. 2016;23(8):614–622.
   PubMed Web of Science ®Google Scholar
• Meissner EG, Wu D, Osinusi A, et al. Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome. J Clin Invest. 2014;124(8):3352–3363.
   PubMed Web of Science ®Google Scholar
• Sidharthan S, Kohli A, Sims Z, et al. Utility of hepatitis C viral load monitoring on direct-acting antiviral therapy. Clin Infect Dis. 2015;60(12):1743–1751.
   PubMed Web of Science ®Google Scholar
• Naggie S, Marks KM, Hughes M, et al. Sofosbuvir plus ribavirin without interferon for treatment of acute hepatitis C virus infection in HIV-1 infected individuals (SWIFT-C). Hepatology. 2015;62(Suppl 1):748A.
   Google Scholar
• Rodriguez-Torres M, Gaggar A, Shen G, et al. Sofosbuvir for chronic hepatitis C virus infection genotype 1–4 in patients coinfected with HIV. JAIDS J Acquired Immune Defic Syndr. 2015;68(5):543–549.
   PubMed Web of Science ®Google Scholar
• Lawitz E, Freilich B, Link J, et al. A phase 1, randomized, dose‐ranging study of GS‐5816, a once‐daily NS5A inhibitor, in patients with genotype 1–4 hepatitis C virus. J Viral Hepat. 2015;22(12):1011–1019..
   PubMed Web of Science ®Google Scholar
• Lawitz E, Reau N, Hinestrosa F, et al. Efficacy of sofosbuvir, velpatasvir, and GS-9857 in patients with genotype 1 hepatitis C virus infection in an open-label, phase 2 trial. Gastroenterology. 2016 Nov;151(5):893–901 e1.
   PubMed Web of Science ®Google Scholar
• Gane EJ, Kowdley KV, Pound D, et al. Efficacy of sofosbuvir, velpatasvir, and GS-9857 in patients with hepatitis C virus genotype 2, 3, 4, or 6 infections in an open-label, phase 2 trial. Gastroenterology. 2016 Nov;151(5):902–909.
   PubMed Web of Science ®Google Scholar
• Gane EJ, Schwabe C, Hyland RH, et al. Efficacy of the combination of sofosbuvir, velpatasvir, and the ns3/4a protease inhibitor GS-9857 in treatment-naive or previously treated patients with hepatitis C virus genotype 1 or 3 infections. Gastroenterology. 2016 Sep;151(3):448–56 e1.
   PubMed Web of Science ®Google Scholar
• Lawitz E, Poordad F, Wells J, et al. Sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin in direct-acting antiviral-experienced patients with genotype 1 hepatitis C virus. Hepatology. 2017 Jun;65(6):1803–1809.
   PubMed Web of Science ®Google Scholar
• Aghemo A, Buti M Hepatitis C therapy: game over! Gastroenterology. 2016 Nov;151(5):795–798.
   PubMed Web of Science ®Google Scholar
• Chahine EB, Kelley D, Childs-Kean LM. Sofosbuvir/velpatasvir/voxilaprevir: a pan-genotypic direct-acting antiviral combination for hepatitis C. Ann Pharmacother. 2018 Apr;52(4):352–363.
   PubMed Web of Science ®Google Scholar
• Bourlière M, Gordon SC, Flamm SL, et al. Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection. N Engl J Med. 2017;376(22):2134–2146.
   PubMed Web of Science ®Google Scholar
• Jacobson IM, Lawitz E, Gane EJ, et al. Efficacy of 8 weeks of sofosbuvir, velpatasvir, and voxilaprevir in patients with chronic HCV infection: 2 phase 3 randomized trials. Gastroenterology. 2017;153(1):113–122.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency: Vosevi. [cited 2018 Mar]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004350/human_med_002153.jsp&mid=WC0b01ac058001d124
   Google Scholar
• Deterding K, Spinner CD, Schott E, et al. Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study. Lancet Infect Dis. 2017 Feb;17(2):215–222.
   PubMed Web of Science ®Google Scholar